PHYSIOLOGICAL CHARACTERISTICS OF THE PANCREATIC HORMONE AMILINE AS AN ENDOGENOUS REGULATORY FACTOR

Luts Yu. P., Lukyantseva Н. V., Pastukhova V. A., Kotlyarenko L. T., Oliinyk T. M.

LITERATURE REVIEWS

Scentific article

Abstract. An urgent issue of modern physiology of the digestive and metabolic organs is the issue of studying the deep mechanisms of humoral regulation of the functions of the gastrointestinal tract. Despite the fact that the features of the synthesis and mechanisms of action of the main hormonal factors of the gastroenteropancreatic endocrine system have been studied quite well, there are still certain gaps in this issue. One of such white spots until recently was the question of the peculiarities of synthesis, secretion, mechanism of action and degradation of one of the pancreatic hormones – amylin. The information available in the scientific literature about this hormone is not fully disclosed or is too contradictory. Our review is devoted to the peculiarities of the synthesis, secretion and mechanisms of the physiological action of this polypeptide factor, which is characterized by a number of autocrine and paracrine effects, as well as a systemic effect on a number of functional processes. Based on the analyzed modern scientific sources, it can be concluded that the peptide hormone amylin is a normal physiological product of the secretory activity of ?-cells of the islets of Langengars of the pancreas, which, together with the hormones insulin and glucagon, takes part in the regulation of glucose homeostasis. In addition, amylin is one of the endogenous regulators of maintaining homeostasis of the gastric mucosa by changing the ratio between the factors of aggression and the defense system towards defense mechanisms, which helps to reduce the risk and degree of ulcerative damage to the mucous membrane. In addition to the above, the effects of amylin are characterized by a number of systemic effects, which include a vasoactive effect, a decrease in the concentration of calcium in the blood, an improvement in memory, participation in the regulation of eating behavior and blood pressure, etc.

amylin, β-cells of the islets of Langengars, pancreas.

1. Akter R, Cao P, Noor H, Ridgway Z, Tu LH, Wang H et al. Islet amyloid polypeptide: Structure, function, and pathophysiology. J. Diabetes Res. 2015;2016:ID2798269. doi: 10.1155/2016/2798269.
2.  Pillay K, Govender P. Amylin uncovered: a review on the polypeptide responsible for type II diabetes. Biomed Res Int. 2013;2013: ID826706. doi: 10.1155/2013/826706.
3. da Silva DC, Fontes GN, Erthal LC, Lima LM. Amyloidogenesis of the amylin analogue pramlintide. Biophys. Chem. 2016;2(19):1-8.
4. Qi D, Cai K, O. Wang O. Fatty acids induce amylin expression and secretion by pancreatic beta-cells, Am J. Physiol. Endocrinol. Metab. 2010;298(1):99-107.
5. Hu R, Zhang M, Chen H, Jiang B, Zheng J. Cross-seeding interaction between beta-amyloid and human islet amyloid polypeptide. ACS Chem Neurosci. 2015;6(10):1759-68. doi: 10.1021/acschemneuro.5b00192.
6. Volkov VN. Novye pankreaticheskie gormony: amylin. Universum: Мedicina I pharmakologiya : elektron. nauchn. zhurnal. 2014;11(12):1- 23. [in Russian]
7. Naot D, Musson DS, Cornish J. The Activity of Peptides of the Calcitonin Family in Bone. Physiol Rev. 2019;99(1):781-805. doi: 10.1152/ physrev. 00066.2017.
8. Bower RL, Yule L, Rees TA, Deganutti G, Hendrikse ER, Harris PW, et al. Molecular Signature for Receptor Engagement in the Metabolic Peptide Hormone Amylin. ACS Pharmacol Transl Sci. 2018 Apr 23;1(1):32-49. doi: 10.1021/acsptsci.8b00002.
9. Sonne N, Karsdal MA, Henriksen K. Mono and dual agonists of the amylin, calcitonin, and CGRP receptors and their potential in metabolic diseases. Mol Metab. 2020 Nov 7;6(448):1-15. doi: 10.1016/j.molmet.2020.101109.
10. Hay DL. Amylin. Headache. 2017;57(2):89-96. doi: 10.1111/head.13077.
11. Hay DL, Chen S, Lutz TA, Parkes DG, Roth JD. Amylin: Pharmacology, Physiology, and Clinical Potential. Pharmacol Rev . 2015;67(3):564- 600. doi: 10.1124/pr.115.010629;
12. Jorsal T, Rungby J, Knop FK, Vilsboll T. GLP-1 and Amylin in the Treatment of Obesity. Curr Diab Rep. 2016;16(1):1.
13. Liang YL,Khoshouei M, Radjainia M,Zhang Y,Glukhova A,Tarrasch J, Thal DM, et al. Phase-platecryo-EM structureof a class B GPCR-Gproteincomplex. Nature. 2017;5466:118-123. doi: 10.1038/nature22327.
14. Pham V, Zhu Y, Maso ED, Reynolds CA, Deganutti G, Atanasio S, Hick CA et al. Deconvoluting the Molecular Control of Binding and Signaling at the Amylin 3 Receptor: RAMP3 Alters Signal Propagation through Extracellular Loops of the Calcitonin Receptor. ACS Pharmacol Transl Sci. 2019 Mar 18;2(3):183-197. doi: 10.1021/acsptsci.9b00010.
15. Noh D, Bower RL, Hay DL, Zhyvoloup A, Raleigh DP. Analysis of Amylin Consensus Sequences Suggests That Human Amylin Is Not Optimized to Minimize Amyloid Formation and Provides Clues to Factors That Modulate Amyloidogenicity. ACS Chem Biol. 2020 Jun 19;15(6):1408-1416.
16. Aldras Y, Singh S, Bode K, Bhowmick DC, Jeremic A, O’Halloran DM. An inducible model of human amylin overexpression reveals diverse transcriptional changes. Neurosci Lett. 2019 Jun 21;704:212-219. doi: 10.1016/j.neulet.2019.04.016.
17. Qiu WQ. Amylin and its G-protein-coupled receptor: A probable pathological process and drug target for Alzheimer’s disease. Neuroscience. 2017 Jul 25;356:44-51. doi: 10.1016/j.neuroscience.2017.05.024.
18. Muller TD, Finan B, Clemmensen C, DiMarchi RD, Tschop MH. The New Biology and Pharmacology of Glucagon. Physiol Rev. 2017;97(2):721-766. doi: 10.1152/physrev.00025.2016.
19. Larsen AT, Sonne N, Andreassen KV, Karsdal MA. The Calcitonin Receptor Plays a Major Role in Glucose Regulation as a Function of Dual Amylin and Calcitonin Receptor Agonist Therapy. J Pharmacol Exp Ther. 2020;374(1):74-83. doi: 10.1124/jpet.119.263392.
20. Ferraz-Amaro I, López-Mejias R, Tejera-Segura B, de Vera-González AM, Ubilla B, Olmos JM, 4, José Luis Hernández JL et al. Amylin in the insulin resistance of patients with rheumatoid arthritis. Clin Exp Rheumatol. 2018;36(3):421-7.
21. Ratha BN, Kar RK, Kalita S, Raha S, Singha A, Garai K, B et al. Sequence specificity of amylin-insulin interaction: a fragment-based insulin fibrillation inhibition study. Biochimic and Biophysic Acta Proteins Proteom. 2019;1867(4):405-415. doi: 10.1016/j.bbapap.2019.01.007.
22. Hieronymus L, Griffin S. Role of Amylin in Type 1 and Type 2 Diabetes. Diabetes Educ. 2015;41(1):47-56.
23. Young А. Effects in skeletal muscle. Adv Pharmacol. 2005;52:209-28. doi: 10.1016/S1054-3589(05)52011-8.
24. Moreno P, Acitores A, Gutiérrez-Rojas I, Nuche-Berenguer B, El Assar M, Rodriguez ML, et al. Amylin effect in extrapancreatic tissues participating in glucose homeostasis, in normal, insulin-resistant and type 2 diabetic state. Peptides. 2011;32(10):2077-85.
25. Camilleri M. Gastrointestinal hormones and regulation of gastric emptying. Curr Opin Endocrinol Diabetes Obes. 2019;26(1):3-10. doi: 10.1097/MED. 0000000000000448.
26. Lutz TA. Pancreatic amylin as a centrally acting satiating hormone. Curr Drug Targets. 2005;6(2):181-9. doi: 10.2174/1389450053174596.
27. .Xie J, Guo J, Kanwal Z, Wu M, Lv X, Ibrahim NA, et al. Calcitonin and Bone Physiology: In Vitro, In Vivo, and Clinical Investigations. Int Jour Endocrinol. 2020 Sep 10;2020:ID3236828. doi: 10.1155/2020/3236828.
28. Kowalczyk R, Brimble MA, Callon KE, Watson M, Cornish J. How to blast osteoblasts? Novel dicarba analogues of amylin-(1-8) to treat osteoporosis. Bioorg Med Chem. 2012 Oct 15;20(20):6011-8. doi: 10.1016/j.bmc.2012. 08.053.
29. Wojcik MH, Meenaghan E, Lawson EA, Misra M, Klibanski A, Miller KK. Reduced amylin levels are associated with low bone mineral density in women with anorexia nervosa. Bone. 2010;46(3):796-800. doi: 10.1016/j. bone.2009.11.014.
30. Chandran M. Diabetes Drug Effects on the Skeleton. Calcif Tissue Int. 2017;100(2):133-149. doi: 10.1007/s00223-016-0203-x.
31. Adil M, Khan RA, Kalam A, Venkata SK, Kandhare AD, Ghosh P, et al. Effect of anti-diabetic drugs on bone metabolism: Evidence from preclinical and clinical studies. Pharmacol Rep. 2017;69(6):1328-1340. doi: 10.1016/j. pharep.2017.05.008.
32. Yang J, Jose PA, Zeng C. Gastrointestinal-Renal Axis: Role in the Regulation of Blood Pressure. J Am Heart Assoc. 2017 Mar 6;6(3):e005536. doi: 10.1161/JAHA.117.005536.
33. Okerson T, Chilton RJ. The cardiovascular effects of GLP-1 receptor agonists. Cardiovasc Ther. 2012;30(3):146-55. doi: 10.1111/j.1755- 5922. 2010.00256.x.
34. Kailasam MT, Parmer RJ, Tyrell EA, Henry RR, O’Connor DT. Circulating amylin in human essential hypertension: heritability and early increase in individuals at genetic risk. J Hypertens. 2000;18(11):1611-20. doi: 10.1097/ 00004872-200018110-00012.
35. Zhang XX, Pan YH, Huang YM, Zhao HL. Neuroendocrine hormone amylin in diabetes. World J Diabetes. 2016 May 10;7(9):189-97. doi: 10.4239/wjd.v7.i9.189.
36. Lukyantseva HV, Sergeev IY, Pastukhova VA, Gunina LM. Dinamika sokratitelnoi aktivnosti izolirovannogo koltsevogo preparata aorty krys pod vliyaniem amilina. Ukrainsky morphologichnyi almanah. 2013;11(1):77-8. [in Russian].
37. Lukyantseva HV, Slobobian OM. Morphophunctsionalny processy v krovenosnyh sudynah i spoluchniy tkanyni bruzhi cshuriv paslya vplyvy pancreatychnogo gormony amiliny. Klinichna anatomia ta operatyvna hirurgiya. 2019;18(3):13-17. [in Ukranian].
38. Samonina GE, Kopylova GN, Lukjanzeva GV, Zhuykova SE, Smirnova EA, German SV, et al. Antiulcer effects of amylin: a review. Pathophysiology. 2004;11(1):1-6. doi: 10.1016/j.pathophys.2003.10.008.
39. Cantarella G, Martinez G, Di Benedetto G, Loreto C, Musumeci G, Prato A, et al. Protective effects of amylin on reserpine-induced gastric damage in the rat. Pharmacol Res. 2007;56(1):27-34. doi: 10.1016/j.phrs.2007.03.001.
40. Zaki M, Koduru S, McCuen R, Vuyyuru L, Schubert ML. Amylin, released from the gastric fundus, stimulates somatostatin and thus inhibits histamine and acid secretion in mice. Gastroenterology. 2002;123(1):247-55. doi: 10.1053/gast.2002.34176.
41. Lukyantseva HV, Kopylova GN, Pastukhova VA, Belikova MV, Zinevich YV. Vliyanie amilina na bazalny I stimulirovannuyu sekretornuyu aktivnost tuchnyh kletok. Ukrainsky morphologichny almanah. 2013;11(2):64-6. [in Ukranian].
42. Gyires К. Neuropeptides and gastric mucosal homeostasis. Curr Top Med Chem. 2004;4(1):63-73. doi: 10.2174/1568026043451609.
43. Cantarella G, Di Benedetto G, Martinez G, Loreto C, Clementi C, Cantarella A, et al. Amylin prevents TRAIL-mediated apoptotic effects of reserpine in the rat gastric mucosa. Peptides. 2009;30(8):1466-72. doi: 10.1016/j. peptides.2009.05.005.
44. Cooper ME, Wookey PJ. Amylin-its role in the kidney. Nephrol Dial Transplant. 1997;12(1):8-10. doi: 10.1093/ndt/12.1.8.
45. Mathai ML, Sosa Leon LA, May CN, Thomson CE, McKinley MJ. Amylin induces natriuresis by a central angiotensin-dependent mechanism. Regul Pept. 2005 Aug 15;1301.2:91-6. doi: 10.1016/j.regpep.2005.04.001.
46. Andrew Young А. Renal effects. Adv Pharmacol. 2005;52:251-68. doi: 10.1016/S1054-3589(05)52015-5.
47. Nassar SZ, Badae NM, Issa YA. Effect of amylin on memory and central insulin resistance in a rat model of Alzheimer’s disease. Arch Physiol Biochem. 2020;126(4):326-334. doi: 10.1080/13813455.2018.1534244.
48. Qiu WQ, Au R, Zhu H, Wallack M, Liebson E, Li H, Rosenzweig J et al. Positive association between plasma amylin and cognition in a homebound elderly population. J Alzheimers Dis. 2014;42(2):555-63.
49. Kumar AP, Lee S, Lukman S. Computational and Experimental Approaches to Design Inhibitors of Amylin Aggregation. Curr Drug Targets. 2019;20(16):1680-1694.
50. Reiner DJ, Mietlicki-Baase EG, Olivos DR, McGrath LE, Zimmer DJ, Koch-Laskowski KK et al. Amylin Acts in the Lateral Dorsal Tegmental Nucleus to Regulate Energy Balance Through Gamma-Aminobutyric Acid Signaling. Biol Psychiatry. 2017 Dec 1;82(11):828-38.
51. Kern KA, Mietlicki-Baase EG. Distributed amylin receptor signaling and its influence on motivated behavior. Physiol Behav. 2020 Aug 1;222:ID112958. doi: 10.1016/j.physbeh.2020.112958.
52. Lutz ТА. The interaction of amylin with other hormones in the control of eating. Diabetes Obes Metab. 2013;15(2):99-111. doi: 10.1111/ j.1463-1326. 2012.01670.x.
53. Becskei С, Grabler V, Edwards GL, Riediger T, Lutz TA. Lesion of the lateral parabrachial nucleus attenuates the anorectic effect of peripheral amylin and CCK. Brain Res. 2007 Aug 8;1162:76-84.
54. Mietlicki-Baase EG, Reiner DJ, Cone JJ, Olivos DR, McGrath LE, Zimmer DJ, et al. Amylin modulates the mesolimbic dopamine system to control energy balance. Neuropsychopharmacology. 2015;40(2):372-85. doi: 10. 1038/npp.2014.180.
55. Levin BE, Lutz TA. Amylin and Leptin: Co-Regulators of Energy Homeostasis and Neuronal Development. Trends Endocrinol Metabol. 2017;28(2):153-164. doi: 10.1016/j.tem.2016.11.004.
56. Potes CS, Lutz TA. Brainstem mechanisms of amylin-induced anorexia. Physiol Behav. 2010 Jul 14;100(5):511-8. doi: 10.1016/j. physbeh.2010. 03.001.
57. Trevaskis JL, Parkes DG, Roth JD. Insights into amylin-leptin synergy. Trends Endocrinol Metab. 2010;21(8):473-9.
58. Lutz TA, Foll CL. Endogenous amylin contributes to birth of microglial cells in arcuate nucleus of hypothalamus and area postrema during fetal development. Am J Physiol Regul Integr Comp Physiol. 2019 Jun 1;316(6):791-801.doi: 10.1152/ajpregu.00004.2019.
59. Wang E, Zhu H, Wang X, Gower AC, Wallack M, Blusztajn JK, et al. Amylin treatment reduces neuroin flammation and ameliorates abnormal patterns of gene expression in the cerebral cortex of an Alzheimer’s disease mouse model. J. Alzheimers Dis. 2017;56:47-61.
60. Mietlicki-Baase EG. Amylin in Alzheimer’s disease: Pathological peptide or potential treatment? Neuropharmacology. 2018 Jul 1;136:287- 97. doi: 10.1016/j.neuropharm.2017.12.016.
61. Zhang Y, Song W. Islet amyloid polypeptide: Another key molecule in Alzheimer’s pathogenesis? Prog. Neurobiol. 2017;153:100-20.

«Bulletin of problems biology and medicine» Issue 1 (159), 2021 year, 287-291 pages, index UDK 612.018:577.175.72

10.29254/2077-4214-2021-1-159-287-291